β-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling

Circulation

Volumn 130, Issue 20, 2014, Pages 1800-1811

  Tilley, Douglas G ^a   Zhu, Weizhong ^a   Myers, Valerie D ^a   Barr, Larry A ^a   Gao, Erhe ^a   Li, Xue ^b   Song, Jianliang ^a   Carter, Rhonda L ^a   Makarewich, Catherine A ^a   Yu, Daohai ^a   Troupes, Constantine D ^a   Grisanti, Laurel A ^a   Coleman, Ryan C ^a   Koch, Walter J ^a   Houser, Steven R ^a   Cheung, Joseph Y ^a   Feldman, Arthur M ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adrenergic; Beta; Cardiomyopathies; Myocardial failure; Myocardium; Receptors; Vasopressin type 1A receptor

Indexed keywords

BETA ADRENERGIC RECEPTOR; CALCIUM; CYCLIC AMP; G PROTEIN RECEPTOR KINASE; PROTEIN KINASE; UNCLASSIFIED DRUG; VASOPRESSIN V1A RECEPTOR; ARGIPRESSIN; FORSKOLIN; G PROTEIN COUPLED RECEPTOR KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; HYBRID PROTEIN; INDOLE DERIVATIVE; ISOPRENALINE; PYRROLIDINE DERIVATIVE; RELCOVAPTAN; ROLIPRAM; VASOPRESSIN RECEPTOR; VASOPRESSIN RECEPTOR ANTAGONIST;

ADULT; ANIMAL CELL; AORTA CONSTRICTION; ARTICLE; BINDING AFFINITY; CALCIUM MOBILIZATION; CELL ISOLATION; CONTROLLED STUDY; EX VIVO STUDY; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CALCIUM SIGNALING; CAT; COMPLICATION; DRUG EFFECTS; GENETICS; HEART CONTRACTION; HEK293 CELL LINE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REPORTER GENE; SECOND MESSENGER; SITE DIRECTED MUTAGENESIS; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; ARGININE VASOPRESSIN; CALCIUM SIGNALING; CARDIOMYOPATHY, HYPERTROPHIC; CATS; CELL LINE, TUMOR; COLFORSIN; CYCLIC AMP; G-PROTEIN-COUPLED RECEPTOR KINASES; GENES, REPORTER; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HEART FAILURE; HEK293 CELLS; HUMANS; INDOLES; ISOPROTERENOL; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTAGENESIS, SITE-DIRECTED; MYOCARDIAL CONTRACTION; PYRROLIDINES; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, VASOPRESSIN; RECOMBINANT FUSION PROTEINS; ROLIPRAM; SECOND MESSENGER SYSTEMS;

EID: 84927786776     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.010434     Document Type: Article

References (57)

1. Bell NH, Schedl HP, Bartter FC. An explanation for abnormal water retention and hypoosmolality in congestive heart failure. Am J Med. 1964;36:351-360.
2. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
3. Gheorghiade M, Pang PS, Ambrosy AP, Lan G, Schmidt P, Filippatos G, Konstam M, Swedberg K, Cook T, Traver B, Maggioni A, Burnett J, Grinfeld L, Udelson J, Zannad F. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are rehospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev. 2012;17:485-509.
4. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med. 1981;305:263-266.
5. Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, Bergmann A, Squire I, van Veldhuisen DJ, Dickstein K; OPTIMAAL Investigators. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J. 2009;30:1187-1194.
6. Knepper MA. Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am J Physiol. 1997;272(pt 2):F3-F12.
7. Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Piña IL, Felker GM, Adams KF Jr, Califf RM, Gheorghiade M; OPTIME-CHF Investigators. Lower serum sodium is associated with increased shortterm mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005;111:2454-2460.
8. Goldsmith SR. Vasopressin as vasopressor. Am J Med. 1987;82:1213-1219.
9. Naitoh M, Suzuki H, Murakami M, Matsumoto A, Arakawa K, Ichihara A, Nakamoto H, Oka K, Yamamura Y, Saruta T. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol. 1994;267(pt 2):H2245-H2254.
10. Yatsu T, Kusayama T, Tomura Y, Arai Y, Aoki M, Tahara A, Wada K, Tsukada J. Effect of conivaptan, a combined vasopressin V(1a) and V(2) receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs. Pharmacol Res. 2002;46:375-381.
11. Li X, Chan TO, Myers V, Chowdhury I, Zhang XQ, Song J, Zhang J, Andrel J, Funakoshi H, Robbins J, Koch WJ, Hyslop T, Cheung JY, Feldman AM. Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through Gαq-mediated cell signaling. Circulation. 2011;124:572-581.
12. Tilley DG. G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function. Circ Res. 2011;109:217-230.
13. Zhu W, Tilley DG, Myers VD, Tsai EJ, Feldman AM. Increased vasopressin 1A receptor expression in failing human hearts. J Am Coll Cardiol. 2014;63:375-376.
14. Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ, Koch WJ. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science. 1998;280:574-577.
15. Funakoshi H, Chan TO, Good JC, Libonati JR, Piuhola J, Chen X, MacDonnell SM, Lee LL, Herrmann DE, Zhang J, Martini J, Palmer TM, Sanbe A, Robbins J, Houser SR, Koch WJ, Feldman AM. Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function. Circulation. 2006;114:2240-2250.
16. Hamad EA, Zhu W, Chan TO, Myers V, Gao E, Li X, Zhang J, Song J, Zhang XQ, Cheung JY, Koch W, Feldman AM. Cardioprotection of controlled and cardiac-specific over-expression of A(2A)-adenosine receptor in the pressure overload. PLoS One. 2012;7:e39919.
17. Wang J, Gao E, Rabinowitz J, Song J, Zhang XQ, Koch WJ, Tucker AL, Chan TO, Feldman AM, Cheung JY. Regulation of in vivo cardiac contractility by phospholemman: role of Na+/Ca2+ exchange. Am J Physiol Heart Circ Physiol. 2011;300:H859-H868.
18. Most P, Seifert H, Gao E, Funakoshi H, Völkers M, Heierhorst J, Remppis A, Pleger ST, DeGeorge BR Jr, Eckhart AD, Feldman AM, Koch WJ. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation. 2006;114:1258-1268.
19. Silver LH, Hemwall EL, Marino TA, Houser SR. Isolation and morphology of calcium-tolerant feline ventricular myocytes. Am J Physiol. 1983;245(pt 1):H891-H896.
20. Allen MD, DiPilato LM, Rahdar M, Ren YR, Chong C, Liu JO, Zhang J. Reading dynamic kinase activity in living cells for high-throughput screening. ACS Chem Biol. 2006;1:371-376.
21. Tilley DG, Kim IM, Patel PA, Violin JD, Rockman HA. β-Arrestin mediates beta1-adrenergic receptor-epidermal growth factor receptor interaction and downstream signaling. J Biol Chem. 2009;284:20375-20386.
22. Tilley DG, Nguyen AD, Rockman HA. Troglitazone stimulates beta-arrestin- dependent cardiomyocyte contractility via the angiotensin II type 1A receptor. Biochem Biophys Res Commun. 2010;396:921-926.
23. MacDonnell SM, García-Rivas G, Scherman JA, Kubo H, Chen X, Valdivia H, Houser SR. Adrenergic regulation of cardiac contractility does not involve phosphorylation of the cardiac ryanodine receptor at serine 2808. Circ Res. 2008;102:e65-e72.
24. Bristow MR. Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res. 2011;109:1176-1194.
25. Pontier SM, Percherancier Y, Galandrin S, Breit A, Galés C, Bouvier M. Cholesterol-dependent separation of the beta2-adrenergic receptor from its partners determines signaling efficacy: insight into nanoscale organization of signal transduction. J Biol Chem. 2008;283:24659-24672.
26. De Lean A, Stadel JM, Lefkowitz RJ. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem. 1980;255:7108-7117.
27. Fu Q, Chen X, Xiang YK. Compartmentalization of β-adrenergic signals in cardiomyocytes. Trends Cardiovasc Med. 2013;23:250-256.
28. Violin JD, Dewire SM, Barnes WG, Lefkowitz RJ. G protein-coupled receptor kinase and beta-arrestin-mediated desensitization of the angiotensin II type 1A receptor elucidated by diacylglycerol dynamics. J Biol Chem. 2006;281:36411-36419.
29. Harris DM, Chen X, Pesant S, Cohn HI, MacDonnell SM, Boucher M, Vinge LE, Raake P, Moraca SR, Li D, Most P, Houser SR, Koch WJ, Eckhart AD. Inhibition of angiotensin II Gq signaling augments betaadrenergic receptor mediated effects in a renal artery stenosis model of high blood pressure. J Mol Cell Cardiol. 2009;46:100-107.
30. Dorn GW 2nd, Tepe NM, Wu G, Yatani A, Liggett SB. Mechanisms of impaired beta-adrenergic receptor signaling in G(alphaq)-mediated cardiac hypertrophy and ventricular dysfunction. Mol Pharmacol. 2000;57:278-287.
31. Jenie RI, Nishimura M, Fujino M, Nakaya M, Mizuno N, Tago K, Kurose H, Itoh H. Increased ubiquitination and the crosstalk of G protein signaling in cardiac myocytes: involvement of Ric-8B in Gs suppression by Gq signal. Genes Cells. 2013;18:1095-1106.
32. Jacobsen SE, Nørskov-Lauritsen L, Thomsen AR, Smajilovic S, Wellendorph P, Larsson NH, Lehmann A, Bhatia VK, Bräuner-Osborne H. Delineation of the GPRC6A receptor signaling pathways using a mammalian cell line stably expressing the receptor. J Pharmacol Exp Ther. 2013;347:298-309.
33. Kamal FA, Travers JG, Blaxall BC. G protein-coupled receptor kinases in cardiovascular disease: why "where" matters. Trends Cardiovasc Med. 2012;22:213-219.
34. Ryckwaert F, Virsolvy A, Fort A, Murat B, Richard S, Guillon G, Colson PH. Terlipressin, a provasopressin drug exhibits direct vasoconstrictor properties: consequences on heart perfusion and performance. Crit Care Med. 2009;37:876-881.
35. Klingler C, Ancellin N, Barrault MB, Morel A, Buhler JM, Elalouf JM, Clauser E, Lugnier C, Corman B. Angiotensin II potentiates vasopressindependent cAMP accumulation in CHO transfected cells: mechanisms of cross-talk between AT1A and V2 receptors. Cell Signal. 1998;10:65-74.
36. Klingler C, Ancellin N, Barrault MB, Morel A, Corman B. Potentiation of receptor-mediated cAMP production: role in the cross-talk between vasopressin V1a and V2 receptor transduction pathways. Biochem J. 1998;330(pt 2):1023-1028.
37. Meszaros JG, Gonzalez AM, Endo-Mochizuki Y, Villegas S, Villarreal F, Brunton LL. Identification of G protein-coupled signaling pathways in cardiac fibroblasts: cross talk between G(q) and G(s). Am J Physiol Cell Physiol. 2000;278:C154-C162.
38. Budd DC, Challiss RA, Young KW, Tobin AB. Cross talk between m3-muscarinic and beta(2)-adrenergic receptors at the level of receptor phosphorylation and desensitization. Mol Pharmacol. 1999;56:813-823.
39. Mandyam CD, Thakker DR, Christensen JL, Standifer KM. Orphanin FQ/nociceptin-mediated desensitization of opioid receptor-like 1 receptor and mu opioid receptors involves protein kinase C: a molecular mechanism for heterologous cross-talk. J Pharmacol Exp Ther. 2002;302:502-509.
40. Malhotra R, D'Souza KM, Staron ML, Birukov KG, Bodi I, Akhter SA. G alpha(q)-mediated activation of GRK2 by mechanical stretch in cardiac myocytes: the role of protein kinase C. J Biol Chem. 2010;285:13748-13760.
41. Zhu W, Tilley DG, Myers VD, Coleman RC, Feldman AM. Arginine vasopressin enhances cell survival via a G protein-coupled receptor kinase 2/β-arrestin1/extracellular-regulated kinase.-dependent pathway in H9c2 cells. Mol Pharmacol. 2013;84:227-235.
42. Huang ZM, Gold JI, Koch WJ. G protein-coupled receptor kinases in normal and failing myocardium. Front Biosci (Landmark Ed). 2011;16:3047-3060.
43. Vinge LE, Andressen KW, Attramadal T, Andersen Gø, Ahmed MS, Peppel K, Koch WJ, Freedman NJ, Levy FO, Skomedal T, Osnes JB, Attramadal H. Substrate specificities of g protein-coupled receptor kinase-2 and -3 at cardiac myocyte receptors provide basis for distinct roles in regulation of myocardial function. Mol Pharmacol. 2007;72:582-591.
44. Heitzler D, Durand G, Gallay N, Rizk A, Ahn S, Kim J, Violin JD, Dupuy L, Gauthier C, Piketty V, Crépieux P, Poupon A, Clément F, Fages F, Lefkowitz RJ, Reiter E. Competing G protein-coupled receptor kinases balance G protein and β-arrestin signaling. Mol Syst Biol. 2012;8:590.
45. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319-1331.
46. Lanfear DE, Sabbah HN, Goldsmith SR, Greene SJ, Ambrosy AP, Fought AJ, Kwasny MJ, Swedberg K, Yancy CW, Konstam MA, Maggioni AP, Zannad F, Gheorghiade M; EVEREST Trial Investigators. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail. 2013;6:47-52.
47. Feldman AM, Hamad E, Tsai EJ, Zhu W, Tilley DG, Alvarez R, Cheung JY. Vasopressin antagonists for patients with acute heart failure: interpreting new clinical and translational data. Clin Pharmacol Ther. 2014;95:373-375.
48. Indrambarya T, Boyd JH, Wang Y, McConechy M, Walley KR. Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice. Crit Care. 2009;13:R98.
49. Coute RA, Mader TJ, Sherman LD. Outcomes by rescue shock number during the metabolic phase of porcine ventricular fibrillation resuscitation. Am J Emerg Med. 2014;32:586-591.
50. Krismer AC, Lindner KH, Wenzel V, Mayr VD, Voelckel WG, Lurie KG, Strohmenger HU. The effects of endogenous and exogenous vasopressin during experimental cardiopulmonary resuscitation. Anesth Analg. 2001;92:1499-1504.
51. Mayr VD, Wenzel V, Voelckel WG, Krismer AC, Mueller T, Lurie KG, Lindner KH. Developing a vasopressor combination in a pig model of adult asphyxial cardiac arrest. Circulation. 2001;104:1651-1656.
52. Voelckel WG, Lurie KG, McKnite S, Zielinski T, Lindstrom P, Peterson C, Krismer AC, Lindner KH, Wenzel V. Comparison of epinephrine and vasopressin in a pediatric porcine model of asphyxial cardiac arrest. Crit Care Med. 2000;28:3777-3783.
53. Voelckel WG, Lurie KG, McKnite S, Zielinski T, Lindstrom P, Peterson C, Wenzel V, Lindner KH, Benditt D. Effects of epinephrine and vasopressin in a piglet model of prolonged ventricular fibrillation and cardiopulmonary resuscitation. Crit Care Med. 2002;30:957-962.
54. Gueugniaud PY, David JS, Chanzy E, Hubert H, Dubien PY, Mauriaucourt P, Bragança C, Billères X, Clotteau-Lambert MP, Fuster P, Thiercelin D, Debaty G, Ricard-Hibon A, Roux P, Espesson C, Querellou E, Ducros L, Ecollan P, Halbout L, Savary D, Guillaumée F, Maupoint R, Capelle P, Bracq C, Dreyfus P, Nouguier P, Gache A, Meurisse C, Boulanger B, Lae C, Metzger J, Raphael V, Beruben A, Wenzel V, Guinhouya C, Vilhelm C, Marret E. Vasopressin and epinephrine vs. epinephrine alone in cardiopulmonary resuscitation. N Engl J Med. 2008;359:21-30.
55. Mentzelopoulos SD, Malachias S, Chamos C, Konstantopoulos D, Ntaidou T, Papastylianou A, Kolliantzaki I, Theodoridi M, Ischaki H, Makris D, Zakynthinos E, Zintzaras E, Sourlas S, Aloizos S, Zakynthinos SG. Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest: a randomized clinical trial. JAMA. 2013;310:270-279.
56. Mentzelopoulos SD, Zakynthinos SG, Siempos I, Malachias S, Ulmer H, Wenzel V. Vasopressin for cardiac arrest: meta-analysis of randomized controlled trials. Resuscitation. 2012;83:32-39.
57. Ong ME, Tiah L, Leong BS, Tan EC, Ong VY, Tan EA, Poh BY, Pek PP, Chen Y. A randomised, double-blind, multi-centre trial comparing vasopressin and adrenaline in patients with cardiac arrest presenting to or in the Emergency Department. Resuscitation. 2012;83:953-960.